AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Inovio Pharmaceuticals, Inc.
Video analysis: INO
All videosNo video analysis for this stock yet. Request one from our team.
News: INO
Inovio Pharmaceuticals, Inc. (INO) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript
Inovio Pharmaceuticals, Inc. (INO) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript
Inovio Nears FDA Decision on INO-3107 as Oct. 30 PDUFA Date Looms
Inovio Pharmaceuticals NASDAQ: INO said its biologics license application for INO-3107, an investigational DNA medicine for recurrent respiratory papillomatosis, or RRP, remains under U.S. Food and Drug Administration review, with a target action date of Oct. 30.
Inovio Pharmaceuticals Nears Oct. 30 FDA Decision for INO-3107 in RRP
Inovio Pharmaceuticals NASDAQ: INO is approaching an October 30 PDUFA date for INO-3107, its lead DNA medicine candidate for recurrent respiratory papillomatosis, or RRP, President and CEO Jacky Shea said during a Cantor Fitzgerald fireside chat.
Inovio Pharmaceuticals, Inc. (INO) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Inovio Pharmaceuticals, Inc. (INO) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Bet on 5 Top-Ranked Stocks With Rising P/E
Tap these five stocks - CURI, INO, GDS, NMG and CCOI - with increasing P/E ratios to try out an out-of-the-box approach.
INOVIO to Participate in Upcoming Investor Conferences
PLYMOUTH MEETING, Pa., Sept. 1, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer and infectious diseases, today announced that it will participate in the following investor conferences: Cantor Global Healthcare Conference (New York) Date: Wednesday, September 9 Fireside Chat: 3:20 PM ET Webcast: https://sqps.onstreamsecure.com/origin/enliven/players/EnlivenPlayer.html?customerId=22&eventId=99315971&checkCompany=1&checkEmail=1&checkName=1 H.C.
Inovio Pharmaceuticals Q2 Earnings Call Highlights
Inovio Pharmaceuticals NASDAQ: INO said the U.S. Food and Drug Administration has completed several key steps in its review of the company's biologics license application for INO-3107, an investigational treatment for recurrent respiratory papillomatosis, or RRP, while the company continues preparations for a potential commercial launch.
Inovio Pharmaceuticals, Inc. (INO) Q2 2026 Earnings Call Transcript
Inovio Pharmaceuticals, Inc. (INO) Q2 2026 Earnings Call Transcript
